The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Open accessAbstract
BACKGROUND: Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with lenalidomide and rituximab is an immunomodulatory regimen that has shown promising activity in patients with indolent B-cell non-Hodgkin's lymphoma. METHODS: We conducted this multicenter, international, phase 3 superiority trial to evaluate rituximab plus lenalidomide, as compared with rituximab plus chemotherapy, in patients with previously untreated follicular lymphoma. Patients were randomly assigned to receive one of the two regimens, followed by maintenance monotherapy with rituximab. Treatment with rituximab plus lenalidomide consisted of 18 cycles of the two drugs, followed by rituximab maintenance therapy every 8 weeks for 12 cycles (six additional doses). Treatment with rituximab plus chemotherapy consisted of the investigator's choice of one of three rituximab-based regimens, followed by maintenance monotherapy with rituximab every 8 weeks for 12 cycles. The primary end points were complete response (confirmed or unconfirmed) at 120 weeks and progression-free survival. RESULTS: A total of 1030 patients were randomly assigned to receive rituximab plus lenalidomide (513 patients) or rituximab plus chemotherapy (517 patients). The rate of confirmed or unconfirmed complete response at 120 weeks was similar in the two groups: 48% (95% confidence interval [CI], 44 to 53) in the rituximab-lenalidomide group and 53% (95% CI, 49 to 57) in the rituximab-chemotherapy group (P=0.13). The interim 3-year rate of progression-free survival was 77% (95% CI, 72 to 80) and 78% (95% CI, 74 to 82), respectively. A higher percentage of patients in the rituximab-chemotherapy group had grade 3 or 4 neutropenia (32% vs. 50%) and febrile neutropenia of any grade (2% vs. 7%), and a higher percentage of patients in the rituximab-lenalidomide group had grade 3 or 4 cutaneous reactions (7% vs. 1%). CONCLUSIONS: Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and rituximab plus chemotherapy (with both regimens followed by rituximab maintenance therapy). The safety profile differed in the two groups. (Funded by Celgene; RELEVANCE ClinicalTrials.gov numbers, NCT01476787 and NCT01650701 , and EudraCT number, 2011-002792-42 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, patients with R/R chronic lymphocytic leukaemia (CLL) receiving R2 have a ORR of >65%78”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
Rummel, M., Niederle, N., Maschmeyer, G., Banat, G.-A., von Grünhagen, U., Losem, C. J., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,512
Salles, G., Seymour, J. F., Offner, F. C., López‐Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,075
Self-citationSmith, T. J., Bohlke, K., Lyman, G. H., Carson, K. R., Crawford, J., Cross, S. J., Goldberg, J. M., Khatcheressian, J. L., Leighl, N. B., Perkins, C. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3488 · Cited by 907
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Marcus, R. E., Davies, A. J., Ando, K., Klapper, W., Opat, S., Owen, C., Phillips, E. H., Sangha, R. S., Schlag, R., Seymour, J. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614598 · Cited by 824
Self-citationLopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Testing for Qualitative Interactions between Treatment Effects and Patient Subsets
Gail, M., & Simon, R. (1985) · Biometrics · doi:10.2307/2530862 · Cited by 651
Brice, P., Bastion, Y., Lepage, É., Brousse, N., Haïoun, C., Moreau, P., Straetmans, N., Tilly, H., Tabah-Fisch, I. M., & Solal‐Céligny, P. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1110 · Cited by 646
Self-citationFlinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., Macdonald, D. A., Hertzberg, M., Kwan, Y., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 644
Self-citationGandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Research works printed but not linked: 1
- Fowler N. Extended dosing lenalidomide with intensified rituximab in untreated indolent NHL. Hematol Oncol 2015;33:200-201. poster.
Cited by
Sorted by citations
Morschhauser, F., Tilly, H., Chaidos, A., McKay, P., Phillips, T., Assouline, S. E., Batlevi, C. L., Campbell, P., Ribrag, V., Damaj, G. L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30441-1 · Cited by 638
Self-citationLeonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00010 · Cited by 434
Self-citationCarbone, A., Roulland, S., Gloghini, A., Younes, A., von Keudell, G., López‐Guillermo, A., & Fitzgibbon, J. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0132-x · Cited by 303
Self-citationDreyling, M. H., Ghielmini, M. E. G., Rule, S. A., Salles, G., Ladetto, M., Tonino, S. H., Herfarth, K. K., Seymour, J. F., & Jerkeman, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.008 · Cited by 270
Self-citationFollicular lymphoma: 2020 update on diagnosis and management
Freedman, A. S., & Jacobsen, E. D. (2019) · American Journal of Hematology · doi:10.1002/ajh.25696 · Cited by 268
Batlevi, C. L., Sha, F., Alperovich, A., Ni, A., Smith, K., Ying, Z., Soumerai, J. D., Caron, P. C., Falchi, L., Hamilton, A., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00340-z · Cited by 209
Follicular lymphoma: 2023 update on diagnosis and management
Jacobsen, E. D. (2022) · American Journal of Hematology · doi:10.1002/ajh.26737 · Cited by 139
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Morschhauser, F., Nastoupil, L. J., Feugier, P., de Colella, J. S., Tilly, H., Palomba, M. L., Bachy, E., Fruchart, C., Libby, E. N., Casasnovas, O., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00843 · Cited by 121
Self-citationMolecular mechanisms of thalidomide and its derivatives
Ito, T., & Handa, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.016 · Cited by 123
Silkenstedt, E., Salles, G. A., Campo, E., & Dreyling, M. H. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02705-8 · Cited by 129
Self-citationLuminari, S., Manni, M., Galimberti, S., Versari, A., Tucci, A., Boccomini, C., Farina, L., Olivieri, J., Marcheselli, L., Guerra, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01234 · Cited by 96
Boellaard, R., Buvat, I., Nioche, C., Ceriani, L., Cottereau, A., Guerra, L., Hicks, R. J., Kanoun, S., Kobe, C., Loft, A., et al. (2024) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267789 · Cited by 74
Casulo, C., Larson, M. C., Lunde, J. J., Habermann, T. M., Lossos, I. S., Wang, Y., Nastoupil, L. J., Strouse, C. S., Chihara, D., Martin, P., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00033-3 · Cited by 68
Anti-CD20 treatment for B-cell malignancies: current status and future directions
Klein, C., Jamois, C., & Nielsen, T. G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1822318 · Cited by 68
Zhu, J., Ma, J., & Union for China Lymphoma Investigators of the Chinese Society of Clinical Oncology (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.01 · Cited by 65
Zucca, E., Rondeau, S., Vanazzi, A., Østenstad, B., Mey, U., Rauch, D., Wahlin, B. E., Hitz, F., Hernberg, M., Johansson, A., et al. (2019) · Blood · doi:10.1182/blood-2018-10-879643 · Cited by 63
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
Matasar, M. J., Luminari, S., Barr, P. M., Barta, S. K., Danilov, A. V., Hill, B. T., Phillips, T. J., Jerkeman, M., Magagnoli, M., Nastoupil, L. J., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0138 · Cited by 66
Westin, J. R., Davis, R. E., Feng, L., Hagemeister, F. B., Steiner, R. E., Lee, H. J., Fayad, L., Nastoupil, L. J., Ahmed, S., Rodriguez, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00597 · Cited by 60
Self-citationDiagnosis and management of follicular lymphoma: A comprehensive review
Dada, R. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13271 · Cited by 60
Follicular lymphoma: The long and winding road leading to your cure?
Gordon, M. J., Smith, M. R., & Nastoupil, L. J. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100992 · Cited by 56
Emerging therapies in mantle cell lymphoma
Hanel, W. G., & Epperla, N. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00914-1 · Cited by 50
Lew, T. E., & Seymour, J. F. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01295-3 · Cited by 51
Song, Y., Liu, Y., Li, Z., Li, L., Su, H., Jin, Z., Zuo, X., Wu, J., Zhou, H., Li, K., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00134-x · Cited by 50
Kurz, K. S., Kalmbach, S., Ott, M., Staiger, A. M., Ott, G., & Horn, H. (2023) · Cancers · doi:10.3390/cancers15030785 · Cited by 50
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Bartlett, N. L., Hahn, U., Kim, W. S., Fleury, I., Laribi, K., Bergua, J., Bouabdallah, K. K., Forward, N. A., Bijou, F. D., Macdonald, D. A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02242 · Cited by 49
Self-citationChiu, H., Trisal, P., Bjorklund, C. C., Carrancio, S., Toraño, E. G., Guarinós, C., Papazoglou, D., Hagner, P. R., Beldi‐Ferchiou, A., Tarte, K., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15797 · Cited by 48
Self-citationSaleem, K., Franz, J. K., Klem, M. L., Yabes, J. G., Boyiadzis, M. M., Jones, J. R., Shaikh, N., & Lontos, K. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00289-7 · Cited by 50
Sortais, C., Lok, A., Tessoulin, B., Gastinne, T., Mahé, B., Dubruille, V., Blin, N., Touzeau, C., Moreau, A., Bossard, C., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04025-2 · Cited by 47
Ansell, S. M., & Lin, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129206 · Cited by 48
Strati, P., Ahmed, M. A., Fowler, N. H., Nastoupil, L. J., Samaniego, F., Fayad, L., Hagemeister, F. B., Romaguera, J. E., Rodriguez, M. A., Wang, M. L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.230649 · Cited by 44
Self-citationBi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
Dalle, I. A., Duléry, R., Moukalled, N. M., Ricard, L., Stocker, N., Cheikh, J. E., Mohty, M., & Bazarbachi, A. A. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00989-w · Cited by 42
Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm
Laurent, C., Dietrich, S., & Tarte, K. (2023) · Blood · doi:10.1182/blood.2023021000 · Cited by 47
How we treat mature B-cell neoplasms (indolent B-cell lymphomas)
Lumish, M. A., Falchi, L., Imber, B. S., Scordo, M., von Keudell, G., & Joffe, E. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01018-6 · Cited by 44
Laurent, C., Adélaı̈de, J., Guillé, A., Tesson, B. M., Gat, E., Evrard, S., Escudié, F., Syrykh, C., Canioni, D., Fabiani, B., et al. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001726 · Cited by 40
Self-citationImmunomodulatory Drugs for the Treatment of B Cell Malignancies
Ioannou, N., Jain, K., & Ramsay, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168572 · Cited by 41
Development of new agents for peripheral T-cell lymphoma
Ito, Y., Makita, S., & Tobinai, K. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1572746 · Cited by 37
Self-citationLenalidomide in follicular lymphoma
Flowers, C. R., Leonard, J. P., & Fowler, N. H. (2020) · Blood · doi:10.1182/blood.2019001751 · Cited by 38
Self-citationPathogenesis of follicular lymphoma: genetics to the microenvironment to clinical translation
Kumar, E. A., Pickard, L., & Okosun, J. (2021) · British Journal of Haematology · doi:10.1111/bjh.17383 · Cited by 42
Perini, G. F., Fischer, T. R. D. C., Gaiolla, R. D., Rocha, T. B., Bellesso, M., Teixeira, L. L. C., Delamain, M. T., Scheliga, A. A. D. S., Ribeiro, G., Neto, J. V. P., et al. (2020) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2020.04.002 · Cited by 36
Cottereau, A., Rebaud, L., Trotman, J., Feugier, P., Nastoupil, L. J., Bachy, E., Flinn, I. W., Haïoun, C., Ysebaert, L., Bartlett, N. L., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.121 · Cited by 36
Self-citationBachy, E., Houot, R., Feugier, P., Bouabdallah, K. K., Bouabdallah, R., Nicolas‐Virelizier, E., Maerevoet, M., Fruchart, C., Snauwaert, S., Gouill, S. L., et al. (2021) · Blood · doi:10.1182/blood.2021013526 · Cited by 36
Self-citationThe investigation and management of follicular lymphoma
McNamara, C., Montoto, S., Eyre, T. A., Ardeshna, K. M., Burton, C., Illidge, T., Linton, K., Rule, S. A., Townsend, W. M., Wong, W. L., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16872 · Cited by 35
Reporting harms more transparently in trials of cancer drugs
Gyawali, B., Shimokata, T., Honda, K., & Ando, Y. (2018) · BMJ · doi:10.1136/bmj.k4383 · Cited by 34
CD19-directed CAR T-cell therapy in B-cell NHL
Kersten, M. J., Spanjaart, A. M., & Thiéblemont, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000668 · Cited by 33
Lymphomas and Their Microenvironment: A Multifaceted Relationship
Menter, T., & Tzankov, A. (2019) · Pathobiology · doi:10.1159/000502912 · Cited by 33
Michot, J., Bouabdallah, R., Vitolo, U., Doorduijn, J. K., Salles, G., Chiappella, A., Zinzani, P. L., Bijou, F. D., Kersten, M. J., Sarmiento, R., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30208-8 · Cited by 32
Self-citationZhang, Y., Zhang, X., Zou, D., Yin, J., Zhang, L., Wang, X., Jia, C., Wang, W. J., Zhao, D., Zhou, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.701507 · Cited by 32
Time for an individualized approach to first-line management of follicular lymphoma
Cartron, G., & Trotman, J. (2022) · Haematologica · doi:10.3324/haematol.2021.278766 · Cited by 32
Self-citationFriedberg, J. W. (2023) · Hematological Oncology · doi:10.1002/hon.3138 · Cited by 31
ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma
Abramson, J. S., Ghosh, N., & Smith, S. M. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_279043 · Cited by 31
Milpied, P., Gandhi, A. K., Cartron, G., Pasqualucci, L., Tarte, K., Nadel, B., & Roulland, S. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.05.002 · Cited by 31
Self-citationLu, T., Zhang, J., Xu-Monette, Z. Y., & Young, K. H. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00432-z · Cited by 34
Yamshon, S., & Ruan, J. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00536-6 · Cited by 30
Prospects in the management of patients with follicular lymphoma beyond first-line therapy
Qualls, D. A., & Salles, G. (2022) · Haematologica · doi:10.3324/haematol.2021.278717 · Cited by 29
Self-citationThe combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
Fowler, N. H., Nastoupil, L. J., de Vos, S., Knapp, M. H., Flinn, I. W., Chen, R., Advani, R. H., Bhatia, S., Martin, P., Mena, R. R., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16424 · Cited by 28
Self-citationFollicular Lymphoma: a Focus on Current and Emerging Therapies
Cahill, K. E. (2022) · ONCOLOGY · doi:10.46883/2022.25920946 · Cited by 28
Clinical advances in epigenetic therapies for lymphoma
Rosenthal, A. C., Munoz, J. L., & Villasboas, J. C. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01452-6 · Cited by 29
Russler‐Germain, D. A., Krysiak, K., Ramirez, C. A., Mosior, M., Watkins, M. P., Gomez, F., Skidmore, Z. L., Trani, L., Gao, F., Geyer, S. M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010779 · Cited by 33
Self-citationHanel, W. G., & Epperla, N. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01113-2 · Cited by 28
Walewski, J. A., Paszkiewicz‐Kozik, E., Michalski, W., Rymkiewicz, G., Szpila, T., Butrym, A. K., Giza, A., Zaucha, J. M., Kalinka‐Warzocha, E., Wieczorkiewicz, A., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16264 · Cited by 26
Menter, T., Tzankov, A., & Dirnhofer, S. (2020) · Hematological Oncology · doi:10.1002/hon.2821 · Cited by 24
Revailler, W., Cottereau, A., Rossi, C., Noyelle, R., Trouillard, T., Morschhauser, F., Casasnovas, O., Thiéblemont, C., Gouill, S. L., André, M. P. E., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12020417 · Cited by 24
Self-citationControversies in the Treatment of Follicular Lymphoma
Hübel, K., Ghielmini, M. E. G., Ladetto, M., & Gopal, A. K. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000317 · Cited by 24
Morschhauser, F., Ghosh, N., Lossos, I. S., Palomba, M. L., Mehta, A., Casasnovas, O., Stevens, D. A., Katakam, S. B., Knapp, A., Nielsen, T. G., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00539-8 · Cited by 23
Self-citationLapenta, C., Donati, S., Spadaro, F., Lattanzi, L., Urbani, F., Macchia, I., Sestili, P., Spada, M., Cox, M. C., Belardelli, F., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02411-y · Cited by 22
The fifth edition of the WHO classification of mature B‐cell neoplasms: open questions for research
Coupland, S. E., Du, M., Ferry, J. A., de Jong, D., Khoury, J. D., Leoncini, L., Naresh, K. N., Ott, G., Siebert, R., Xerri, L., et al. (2024) · The Journal of Pathology · doi:10.1002/path.6246 · Cited by 22
Self-citationAttygalle, A. D., Chan, J. K. C., Coupland, S. E., Du, M., Ferry, J. A., de Jong, D., Gratzinger, D. A., Lim, M. S., Naresh, K. N., Nicolae, A., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2297939 · Cited by 24
Evens, A. M., Hong, F., Habermann, T. M., Advani, R. H., Gascoyne, R. D., Witzig, T. E., Quon, A. S. W., Ranheim, E. A., Ansell, S. M., Cheema, P. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1345 · Cited by 22
Amoozgar, B., Bangolo, A., Habibi, M., Cho, C., & Goy, A. H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115319 · Cited by 21
Follicular lymphoma and macrophages: impact of approved and novel therapies
Gouni, S., Marques-Piubelli, M. L., & Strati, P. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005722 · Cited by 21
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Saleh, K., Cheminant, M., Chiron, D., Burroni, B., Ribrag, V., & Sarkozy, C. (2022) · Cancers · doi:10.3390/cancers14133229 · Cited by 22
Self-citationTherapy-related myeloid neoplasms in lymphoma survivors: Reducing risks
Al-Juhaishi, T. M. S., Khurana, A., & Shafer, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.008 · Cited by 21
Menter, T., Tzankov, A., Zucca, E., Kimby, E. K., Hultdin, M., Sundström, C., Beiske, K., Cogliatti, S., Banz, Y., Cathomas, G., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16414 · Cited by 21
Delfau‐Larue, M., Boulland, M., Beldi‐Ferchiou, A., Feugier, P., Maisonneuve, H., Casasnovas, O., Lemonnier, F., Pica, G. M., Houot, R., Ysebaert, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001955 · Cited by 21
Self-citationIs it time for PET-guided therapy in follicular lymphoma?
Trotman, J., & Pettitt, A. R. (2021) · Blood · doi:10.1182/blood.2020008243 · Cited by 21
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Guo, H., Yang, J., Wang, H., Liu, X., Liu, Y., & Zhou, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1017990 · Cited by 21
Infante, M. S., Salmanton‐García, J., Fernández‐Cruz, A., Marchesi, F., Jakšić, O., Weinbergerová, B., Besson, C., Duarte, R. F., Itri, F., Valković, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.992137 · Cited by 19
Wang, Y., Zhou, S., Qi, X., Yang, F., Maurer, M. J., Habermann, T. M., Witzig, T. E., Wang, M. L., & Nowakowski, G. S. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00598-x · Cited by 18
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
Mohty, R., & Kharfan‐Dabaja, M. A. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221142133 · Cited by 18
Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review
Patel, K. K., Ivanov, A., Jocelyn, T., Hantel, A., Garcia, J. S., & Abel, G. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.14425 · Cited by 22
Laurent, C., Trisal, P., Tesson, B. M., Seth, S., Beyou, A., Roulland, S., Lesne, B., Acker, N. V., Cerapio, J., Chartier, L., et al. (2024) · Blood · doi:10.1182/blood.2024024496 · Cited by 18
Self-citationCheson, B. D., Morschhauser, F., & Martin, P. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.03.009 · Cited by 18
Self-citationCox, M. C., Nusca, S. M., Landro, F. D., Marsilli, G., Stella, G. C., Sigona, M., Ponzelli, F., Passerini, J., Gregorio, F. D., Santoboni, F., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1842396 · Cited by 19
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
Pytlík, R., Polgárová, K., Karolová, J., & Klener, P. (2020) · Vaccines · doi:10.3390/vaccines8040708 · Cited by 17
Mitigating time toxicity in lymphoma and multiple myeloma
Di, M., Su, C. T., Cowan, A. J., Gopal, A. K., & Banerjee, R. K. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2352086 · Cited by 18
Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy
Sircar, A., Chowdhury, S. M., Hart, A., Bell, W. R., Singh, S. V., Sehgal, L., & Epperla, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030904 · Cited by 17
Apostolidis, J. P., Sayyed, A., Darweesh, M., Kaloyannidis, P., & Hashmi, H. A. (2020) · Journal of Immunology Research · doi:10.1155/2020/9350272 · Cited by 17
Sohani, A. R., Maurer, M. J., Giri, S., Pitcher, B. N., Chadburn, A., SAID, J. W., Bartlett, N. L., Czuczman, M. S., Martin, P., Rosenbaum, C. A., et al. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001609 · Cited by 17
Self-citationLenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma
Menard, C., Rossille, D., Dulong, J., Nguyen, T.-T., Papa, I., Latour, M., Bescher, N., Bézier, I., Chouteau, M., Fest, T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003774 · Cited by 17
Self-citationFollicular lymphoma: Update on management and emerging therapies at the dawn of the new decade
Apostolidis, J. P., Mokhtar, N., Omari, R., Darweesh, M., & Hashmi, H. A. (2019) · Hematological Oncology · doi:10.1002/hon.2711 · Cited by 17
B Cell Lymphomas of the GI Tract
Small, S. H., Slonim, L. B., Williams, C. J., & Karmali, R. (2021) · Current Gastroenterology Reports · doi:10.1007/s11894-021-00811-8 · Cited by 16
Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
Leslie, L. A. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00909-1 · Cited by 16
Ollila, T. A., Butera, J. N., Egan, P., Reagan, J. L., Thomas, A. G., Yakirevich, I., MacKinnon, K., Margolis, J. M., McMahon, J. B., Rosati, V., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab079 · Cited by 16
Barraclough, A., Agrawal, S., Talaulikar, D., Chong, G., Yoo, E., Cheah, C. Y., Franco, N. F., Nguyen, B., Mutsando, H., Tahir, F., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284538 · Cited by 16
Kimby, E. K., Lockmer, S., Holte, H., Hagberg, H., Wahlin, B. E., Brown, P. D. N., & Østenstad, B. (2020) · British Journal of Haematology · doi:10.1111/bjh.16692 · Cited by 16
Neelapu, S. S., Adkins, S., Ansell, S. M., Brody, J., Cairo, M. S., Friedberg, J. W., Kline, J. P., Levy, R., Porter, D. L., van Besien, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001235 · Cited by 16
Rodgers, T. D., Casulo, C., Boissard, F., Launonen, A., Parreira, J. M., & Cartron, G. (2021) · Oncology and Therapy · doi:10.1007/s40487-021-00161-5 · Cited by 16
Self-citationIkaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 17
Actualización en el diagnóstico, pronóstico y tratamiento del linfoma folicular
Mozas, P., Sorigué, M., & López‐Guillermo, A. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.03.041 · Cited by 15
Self-citation
Metadata
- Authors
- Morschhauser, F., Fowler, N. H., Feugier, P., Bouabdallah, R., Tilly, H., Palomba, M. L., Fruchart, C., Libby, E. N., Casasnovas, R.-O., Flinn, I. W., Haioun, C., Maisonneuve, H., Ysebaert, L., Bartlett, N. L., Bouabdallah, K., Brice, P., Ribrag, V., Daguindau, N., Le Gouill, S., Pica, G. M., Martin Garcia-Sancho, A., López-Guillermo, A., Larouche, J.-F., Ando, K., Gomes da Silva, M., André, M., Zachée, P., Sehn, L. H., Tobinai, K., Cartron, G., Liu, D., Wang, J., Xerri, L., & Salles, G. A.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- From Université Lille, Centre Hospitalier Universitaire (CHU), Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille (F.M.), CHU Régional de Nancy, Service d’Hématologie, Vandoeuvre lès Nancy (P.F.), Institut Paoli-Calmettes (R.B.) and Department of Pathology, Institut Paoli-Calmettes, Centre de Recherche en Cancerologie de Marseille, INSERM, Centre National de la Recherche Scientifique, Aix-Marseille Université (L.X.), Marseille, Centre Henri Becquerel, Unité 1245 and...
- ORCID
- Morschhauser, Franck
- Fowler, Nathan H.
- Feugier, Pierre
- Tilly, Hervé
- Palomba, M. Lia
- Fruchart, Christophe
- Flinn, Ian W.
- Bartlett, Nancy L.
- Bouabdallah, Kamal
- Brice, Pauline
- Ribrag, Vincent
- Larouche, Jean-François
- Ando, Kiyoshi
- André, Marc
- Zachée, Pierre
- Sehn, Laurie H.
- Tobinai, Kensei
- Cartron, Guillaume
- Wang, Jianming
- Xerri, Luc
- Salles, Gilles A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-09-06
- Volume
- 379
- Issue
- 10
- Pages
- 934-947
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11003525
- OpenAlex
- W2891543930
- Cited by
- 373
- References
- 30
- Citations by year
- 2026: 17 · 2025: 52 · 2024: 38 · 2023: 37 · 2022: 52 · 2021: 62 · 2020: 58 · 2019: 51 · 2018: 5
- FWCI
- 33.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- HAL (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion)
- Funders
- Celgene
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Keywords
- follicular lymphoma, rituximab, lenalidomide, previously untreated lymphoma, rituximab plus chemotherapy, maintenance therapy, complete response, progression-free survival, neutropenia, skin reactions, immunomodulatory therapy, B-cell non-Hodgkin lymphoma, safety and tolerability
- MeSH terms
- Rituximab, Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Lymphoma, Follicular, Male, Middle Aged, Neutropenia, Skin Diseases, Thalidomide, Survival Rate, Disease-Free Survival, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
